Ionis Pharmaceuticals (IONS) Earnings Date & Reports

Ionis reported total revenue of $246 million for the first quarter ended March 31, 2026, surpassing consensus estimates of about $197 million. This represented an 87% year-over-year increase from $132 million, driven by $108 million in commercial revenue (up 42%) including $27 million from TRYNGOLZA and $16 million from DAWNZERA, plus $138 million in R&D revenue featuring $95 million in milestones. Royalties contributed $44 million from SPINRAZA and $11 million from WAINUA.

GAAP operating expenses rose to $364 million from $278 million, reflecting investments in commercialization and R&D ($210 million). Net loss narrowed to $93 million, or $0.56 per share (basic and diluted), significantly better than the $147 million loss or $0.93 per share in Q1 2025 and consensus EPS of -$0.85. Non-GAAP loss from operations improved to $75 million.

Guidance updates included raised 2026 total revenue to $875-900 million, TRYNGOLZA sales of $100-110 million, DAWNZERA $110-120 million, and non-GAAP operating loss of $425-475 million, reflecting strong year-to-date performance.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your investment strategy.

Market Reaction and Investor Sentiment

Following the April 29 release, Ionis shares rose approximately 4% in pre-market trading to around $74.46, reflecting positive investor response to the revenue beat, EPS outperformance, and upward guidance revision. Sentiment appears optimistic, with emphasis on accelerating product launches and upcoming regulatory decisions. Analysts highlighted the commercial momentum as a key driver, though some noted elevated valuation risks in biotech.

Forward Outlook and Key Factors to Monitor

Ionis enters the remainder of 2026 with elevated guidance signaling confidence in its commercial engine. Investors should track TRYNGOLZA's supplemental New Drug Application (sNDA) for sHTG, with a PDUFA target action date of June 30, potentially enabling a late-2026 launch. Similarly, zilganersen's NDA for Alexander disease has a PDUFA date of September 22, marking Ionis' first independent neurology entry.

Partnered programs offer catalysts too: bepirovirsen's PDUFA on October 26 for chronic hepatitis B, plus Phase 3 topline data from pelacarsen (HORIZON for Lp(a)) and eplontersen (CARDIO-TTRansform for ATTR cardiomyopathy) later in the year. These could drive milestone payments and royalties.

Financially, monitor operating expense control amid launch investments, cash burn (now >$1.6 billion runway), and progress toward 2028 cash-flow breakeven. Broader industry dynamics, including reimbursement trends and competition in rare diseases, will influence uptake of TRYNGOLZA and DAWNZERA.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations